nach oben

Clinical and Translational Oncology

Erschienen in:

01.05.2013 | Research Article

Prognostic significance of NSE mRNA in advanced NSCLC treated with gefitinib

verfasst von: Y. Wang, D. Tang, A. Sui, W. Jiao, Y. Luo, M. Wang, R. Yang, Z. Wang, Y. Shen

Erschienen in: Clinical and Translational Oncology | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Current knowledge of the prognostic biomarkers of advanced non-small cell lung cancer (NSCLC) treated with gefitinib is poor. NSE mRNA as a potential prognostic biomarker of the effectiveness of gefitinib treatment in NSCLC, especially in the Chinese population, needs to be further validated.

Patients and Methods

We retrospectively reviewed 168 advanced NSCLC patients treated with gefitinib between May 2006 and July 2010. NSE mRNA was measured using quantitative RT-PCR analysis for correlation with the clinical outcomes.

Results

We found that NSE mRNA expression was inversely correlated with sensitivity to gefitinib in NSCLC patients. Patients without elevated NSE mRNA had a more RR (CR + RR) 45.1 % than elevated 18.9 % (P = 0.0005). Moreover, the time to progression was 6.0 versus 4.2 months, respectively. Log-rank test was marginally significant (χ² = 12.11, P = 0.0007) and Cox multivariate analysis revealed that NSE mRNA (HR = 3.076; 95 % CI 1.943–4.870; P < 0.0001) was an independent prognostic factor of NSCLC patients in the Chinese population.

Conclusion

For NSCLC patients treated with gefitinib, patients without elevated NSE mRNA had a better prognosis than those with elevated NSE mRNA. Pretreatment NSE mRNA holds great potential as a prognostic biomarker in advanced NSCLC. Therefore, it is proposed that NSE mRNA should be routinely detected to screen patients who are more likely to benefit from gefitinib-based treatment.

Christian WJ, Huang B, Rinehart J, Hopenhayn C (2011) Exploring geographic variation in lung cancer incidence in Kentucky using a spatial scan statistic: elevated risk in the Appalachian coal-mining region. Public Health Rep 126:789–796PubMed

Armour AA, Watkins CL (2010) The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer. Eur Respir Rev 19:186–196PubMedCrossRef

Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388PubMedCrossRef

Favoni RE, Pattarozzi A, Lo Casto M et al (2010) Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation. Curr Cancer Drug Targets 10:176–191PubMedCrossRef

Ebert W, Muley T, Trainer C, Dienemann H, Drings P (2002) Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC. Anticancer Res 22:1083–1089PubMed

Satoh H, Ishikawa H, Kurishima K, Yamashita YT, Ohtsuka M, Sekizawa K (2002) Cut-off levels of NSE to differentiate SCLC from NSCLC. Oncol Rep 9:581–583 PubMed:11956631PubMed

Gaafar RM, Surmont VF, Scagliotti GV et al (2011) A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). Eur J Cancer 47:2331–2340 PubMed:21802939PubMedCrossRef

Kester MI, van der Flier WM, Visser A, Blankenstein MA, Scheltens P, Oudejans CB (2011) Decreased mRNA expression of CCL5 [RANTES] in Alzheimer’s disease blood samples. Clin Chem Lab Med. (PubMed:21942811)

Reis PP, Waldron L, Goswami RS et al (2011) mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol 11:46 PubMed:21549012PubMedCrossRef

10.

Fendri A, Kontos CK, Khabir A, Mokdad-Gargouri R, Scorilas A (2011) BCL2L12 is a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma. Mol Med 17:163–171 PubMed:21152697PubMedCrossRef

11.

Schraml P, von Teichman A, Mihic-Probst D et al (2012) Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncol Rep 28:654–658 PubMed:22614944PubMed

12.

Yamaguchi S, Nishimura R, Yaegashi N et al (2012) Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065). Oncol Rep 28:487–493 PubMed:22614251PubMed

13.

He JJ, Zhi K, Liu GF (2011) Predictive value of serum bone sialoprotein in patients with bone metastasis of non-small cell lung cancer. Onkologie 34:584–588 PubMed:22104154PubMedCrossRef

14.

Shen X, Nair CK, Holmberg MJ et al (2011) Impact of left atrial volume in prediction of outcome after cardiac resynchronization therapy. Int J Cardiol 152:13–17 PubMed:20621370PubMedCrossRef

15.

Xu N, Zhang X, Wang X et al (2012) FoxM1 mediated resistance to gefitinib in non-small-cell lung cancer cells. Acta Pharmacol Sin 33:675–681 PubMed:22447226PubMedCrossRef

16.

Chen YJ, Huang WC, Wei YL et al (2011) Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. PLoS ONE 6:e21428 PubMed:21731744PubMedCrossRef

17.

Rosell R, Perez-Roca L, Sanchez JJ et al (2009) Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS ONE 4:e5133 PubMed:19415121PubMedCrossRef

18.

Judde JG, Rebucci M, Vogt N et al (2007) Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response. Int J Cancer 120:1579–1590 PubMed:17205515PubMedCrossRef

19.

Reinmuth N, Thomas M, Meister M, Schnabel PA, Kreuter M (2010) Current data on predictive markers for anti-angiogenic therapy in thoracic tumours. Eur Respir J 36:915–924 PubMed:20889462PubMedCrossRef

20.

Toomey D, Smyth G, Condron C et al (2001) Immune function, telomerase, and angiogenesis in patients with primary, operable nonsmall cell lung carcinoma: tumor size and lymph node status remain the most important prognostic features. Cancer 92:2648–2657 PubMed:11745200PubMedCrossRef

21.

Zych J, Sakowicz A, Radzikowska E, Zaleska J, Rowinska-Zakrzewska E (1997) Neuron-specific enolase (NSE) serum level in non small cell lung cancer—can it be an indicator of tumour chemosensitivity? Rocz Akad Med Bialymst 42(Suppl 1):173–178 PubMed:9337535PubMed

22.

Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE (1991) Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338:1227–1229 PubMed:1719320PubMedCrossRef

23.

Belderbos J, Uitterhoeve L, van Zandwijk N et al (2007) Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972–22973). Eur J Cancer 43:114–121 PubMed:17084621PubMedCrossRef

24.

Chu XY, Hou XB, Song WA, Xue ZQ, Wang B, Zhang LB (2011) Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer in patients with suspicious pulmonary masses: a single center analysis. Cancer Biol Ther 11:995–1000 PubMed:21483235PubMedCrossRef

25.

Tiseo M, Ardizzoni A, Cafferata MA et al (2008) Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer. Anticancer Res 28:507–513 PubMed:18383893PubMed

26.

Dediu M (2011) Controversies in the management of advanced non-small cell lung cancer: maintenance therapy. J BUON 16:431–433 PubMed:22006744PubMed

27.

Rikova K, Guo A, Zeng Q et al (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190–1203 PubMed:18083107PubMedCrossRef

28.

Heibeck TH, Ding SJ, Opresko LK et al (2009) An extensive survey of tyrosine phosphorylation revealing new sites in human mammary epithelial cells. J Proteome Res 8:3852–3861 PubMed:19534553PubMedCrossRef

29.

Jang SM, Kim JW, Kim CH, Kim D, Rhee S, Choi KH (2010) p19(ras) Represses proliferation of non-small cell lung cancer possibly through interaction with neuron-specific enolase (NSE). Cancer Lett 289:91–98 PubMed:19713034PubMedCrossRef

30.

Grimminger PP, Schneider PM, Metzger R, et al (2010) The prognostic role of Bcl-2 mRNA expression in curatively resected non-small cell lung cancer (NSCLC). Lung Cancer 70:82–87 PubMed:20064672

Titel: Prognostic significance of NSE mRNA in advanced NSCLC treated with gefitinib
verfasst von: Y. Wang
D. Tang
A. Sui
W. Jiao
Y. Luo
M. Wang
R. Yang
Z. Wang
Y. Shen
Publikationsdatum: 01.05.2013
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 5/2013
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0939-3

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Prognostic significance of NSE mRNA in advanced NSCLC treated with gefitinib

Abstract

Purpose

Patients and Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Patients and Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2013

Clinical and mutation analysis of four Chinese families with von Hippel-Lindau disease

Cone-beam computed tomography dose monitoring during intensity-modulated radiotherapy in head and neck cancer: parotid glands

Circulating autoantibody to ABCC3 may be a potential biomarker for esophageal squamous cell carcinoma

Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC)

Polymorphisms in HIF-1alpha affect presence of lymph node metastasis and can influence tumor size in squamous-cell carcinoma of the glottic larynx

Advanced or metastatic gastric cancer in elderly patients: clinicopathological, prognostic factors and treatments

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie